Ye Chen

机构：Tongji University, Fujian Medical University, Tsinghua Sichuan Energy Internet Research Institute, First Affiliated Hospital of Fujian Medical University, First Affiliated Hospital of Henan University of Science and Technology, Chengdu Tiger Microwave Technology (China), Second Affiliated Hospital of Zhejiang University, Tongji Hospital, Hubei University of Technology · ORCID：0009-0007-6024-6562

发表论文 20 篇 · 总被引 422 次 · h-index 6

代表论文

• Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial (2023 · The Lancet Oncology · 被引 206)
• First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial (2025 · Nature Medicine · 被引 88)
• Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial (2024 · Nature Medicine · 被引 45)
• Circular RNA EIF3I promotes papillary thyroid cancer progression by interacting with AUF1 to increase Cyclin D1 production (2023 · Oncogene · 被引 19)
• Sustainable Urban Landscape Quality: A User-Perception Framework for Public Space Assessment and Development (2025 · Sustainability · 被引 13)
• A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer (2024 · Med · 被引 8)